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Objectives: To identify factors associated with failure of telaprevir- and boceprevir-
based HCV triple therapy at a tertiary referral center in New York. MethOds: 
Records of 223 patients with genotype 1 HCV mono-infection who initiated triple 
therapy with peg-IFN/RBV plus telaprevir or boceprevir between 5/2011 and 3/2012 
were reviewed. Data were analyzed on an intention-to-treat basis by multivari-
able logistic regression and classification and regression tree models. Results: 
Overall, 172 patients were on telaprevir and 51 were on boceprevir. Median age 
was 57 years, 35% were female, 18% were black, 44% had F3-F4 fibrosis (Fib-4 ≥ 
3.25), 31% were naïve to treatment, 53% had genotype 1a, and 9% of those tested 
had IL28B CC genotype. Overall, 48% completed the expected course of therapy. 
Treatment failure (58% of patients) was associated with insufficient viral suppres-
sion or breakthrough (30%), adverse events (14%), relapse (12%), and loss to follow 
up (2%). Black race increased the risk of failure (OR: 5.92; 95% CI: 2.34-14.96), whereas 
HCV genotype 1b (OR:0.36; 95% CI: 0.18-0.69), higher platelets (OR: 0.91 per 10x103/
µL; 95% CI: 0.86-0.96), and IL28B CC genotype (OR: 0.28; 95% CI: 0.10-0.84) decreased 
the risk. In a classification tree, platelets < 137 x 103/µL were the strongest predictor 
of non-SVR24. The absence of HCV RNA at week 4 (telaprevir) or week 8 (boceprevir) 
were the only on-treatment variables independently (and inversely) related to non-
SVR. cOnclusiOns: Low platelets were an important negative predictor, suggest-
ing that treatment may be more effective if initiated before the onset of advanced 
liver disease and thrombocytopenia.(NIDA031095,NIDDK090317,Janssen)
PIN4
the ImPact oF PNeNumococcal coNjugate vaccINes (Pcv) 
ImmuNIzatIoN Program oN INvasIve PNeumococcal dIsease IN NeW 
taIPeI cIty, taIWaN
Chang C.J.1, Fang C.H.2, Chien L.3, Huang Y.C.2, Shau W.Y.2, Huang L.M.4
1Chang Gung University, Kwei-Shan, Taoyuan, Taiwan, 2Pfizer Limited, New Taipei City, Taiwan, 
3Chang Gung University, Tao-Yuan, Taiwan, 4National Taiwan University Hospital, Taipeu
Objectives: Three PCVs (7-, 10-, and 13-valent) have been launched in Taiwan; 
only PCV10 and PCV13 are available in the current market. The City immunization 
program (CIP) in New Taipei City (NTC) started offering one dose of PCV in 2007 for 
children aged 2-5. PCV7 was provided initially and switched to PCV13 in 2012. To 
date, there is no research on the effectiveness of PCVs in Taiwan. This study evalu-
ated the real-world impact of PCVs on invasive pneumococcal disease (IPD) in NTC, 
the largest population city in Taiwan. MethOds: Data were derived from National 
Immunization Information System and National IPD Reporting System. Descriptive 
analysis was applied to summarize the vaccination trend and characteristics of 
IPD cases. The risk of IPD from vaccine-covered serotypes with PCV was estimated 
using incidence rate ratio (IRR), and the vaccine effectiveness was calculated as 
1- IRR. Vaccinated was defined as children who had at least one dose of PCV. If 
multiple PCVs were used, children were assigned to the PCV with more covered 
serotypes. Results: Total of 321,631 children born in NTC between Jan 1st, 2004 
and June 30th, 2013 were included. There were 183,342 children (58%) vaccinated; 
among these 46.0%, 51.7%, and 1.4% with PCV7, PCV13, PCV10, respectively. PCV10 
was excluded for the risk analysis, due to low utilization. Among 152 identified 
IPD cases, 84 cases (55.3%) were caused by serotype 19A. Most events occurred in 
children 3 (21.7%) and 2 (21.1%) years of age. The adjusted IRR of IPD (PCV-7 covered 
serotypes) for PCV7 was 0.29 (p= 0.012); VE 71%. The adjusted IRR of IPD for PCV13 
(PCV-13 covered serotypes) was 0.2 (p= 0.001); VE 80%. cOnclusiOns: Due to the 
CIP, over half of children 5 years and younger received a PCV in NTC. PCV vaccination 
significantly reduced the risk of IPD.
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Objectives: Influenza burden might be reduced by replacing current trivalent 
influenza vaccines (TIV, containing one B lineage) with quadrivalent vaccines 
(QIV, containing both Yamagata and Victoria influenza B lineages). This study 
(ClinicalTrials.gov: NCT01599390) assessed the potential added benefit of QIV 
versus TIV use on the prevention of influenza-attributable hospitalizations and 
deaths in the United States during 12 influenza seasons (July 1997–April 2009) 
as a consequence of preventing influenza B lineage mismatch. MethOds: 
Hospitalization and mortality data from the Nationwide Inpatient Sample and 
National Vital Statistics System databases, respectively, were used to quantify the 
influenza-attributable burden through virus-guided regression models. Based on 
Reed’s probability model (Reed et al, Vaccine 2012;30:1993-8), a simple multiplier 
model was developed to estimate the “respiratory disease broadly defined” (RDBD) 
outcome rates had B lineage mismatch seasons been avoided. Hospitalizations 
with primary, and deaths with any mention of RDBD diagnostic codes (respiratory 
disease, cough, abnormalities of breathing, fever or viral infections not other-
wise specified) were considered influenza-attributable. The model used avail-
able vaccine coverage data (primary source: CDC Morbidity & Mortality Weekly 
Reports; secondary sources: National Health Interview Survey reports, National 
Immunization Survey, Behavioral Risk Factor Surveillance System) and vaccine 
effectiveness values from the literature. Results: The highest numbers of QIV-
preventable hospitalizations and deaths were attributed to ≥ 75-year-olds: 3,141 
and 461 on average per season, respectively. During the worst mismatched season 
(2007/2008), across all ages, 41% and 28% of influenza-attributable hospitalizations 
medication therapy for diabetes increased from 11.8 to 17.6 million, but the per-
centage of patients receiving prescription medication for diabetes dropped from 
90.5% to 87.5% (p< .001). The mean number of physician’s office visits for treating 
diabetes increased from 45.9 million in 2002 to 55.9 million in 2010, while the 
mean number of visits per treated patient declined from 4.7 to 3.9 during the 
same period. Among the patients used prescription medications, the proportion of 
those using both insulin and oral anti-diabetic medications increased from 14.9% 
in 2002 to 18.4% in 2010. For specific classes of oral anti-diabetic medications, the 
percentage using biguanides increased from 40.1% to 60.5%, in the contrast, use 
of sulfonylureas and thiazolidinediones dropped from 50.1% to 36.1% and 20.7% to 
12.8% respectively. The annual expenditures per user for medications for treating 
diabetes increased from $889 in 2002 to $1026 in 2010. Increasing use of newer 
insulin and thiazoliones was the main driver of recent increases in the medica-
tion expenditures ($10.5 billion in 2002 to $18.1 billion in 2007). cOnclusiOns: 
Increasing costly medication therapy for diabetes is being applied to an increasing 
population. However, the percentage of diabetes patients received medication 
treatment slightly dropped. This suggests that much more attention should be 
directed in reducing the gap between treatment need and use as well as evaluation 
of more costly medication therapy for diabetes.
INFectIoN – clinical outcomes studies
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Objectives: Anaphylaxis is a serious allergic reaction that has been reported as a 
rare adverse drug reaction (ADR) in cephalosporin antibiotics, predominantly cef-
triaxone, causing several deaths. We aimed to evaluate reports of anaphylaxis with 
3rd generation cephalosporins (ATC code= J01DD) using a disproportionality analysis 
of spontaneous adverse event reports. MethOds: Our case-control study identified 
anaphylaxis (cases) or other adverse events (controls) in FAERS from January 2004 to 
September 2012 for 3rd generation cephalosporin antibiotics. Reporting odds ratio 
(ROR) and proportional reporting ratio (PRR) were calculated to estimate risk for 
each 3rd generation cephalosporin. Only primary suspected drugs and initial status 
of reports were studied. Results: Of 9315 eligible ADR reports for 3rd generation 
cephalosporins, 278 (3%) anaphylaxis ADRs were reported, with 100 (36%) deaths, 
68 (25%) hospitalizations, and 52 (19%) life-threatening events. Ceftriaxone was the 
most commonly reported cephalosporin exposure among anaphylaxis cases (n= 189, 
67.9%). Of the anaphylaxis cases associated with ceftriaxone, death was reported in 
43%, hospitalization in 24%, and life-threatening events in 21% of cases. The odds 
of exposure was significantly higher with cefoperazone (ROR 3.88, 95% confidence 
interval [CI] 2.71-5.56) and ceftriaxone (ROR= 1.92, CI= 1.49-2.48) and significantly 
lower with cefdinir (ROR= 0.15, CI= 0.08-0.29) and cefotaxime (ROR= 0.31, CI= 0.12-
0.84) among cases compared to controls. Similarly, PRR indicated a significantly 
increased risk of anaphylaxis with cefoperazone (PRR= 3.60, CI= 2.60-5.00) and cef-
triaxone (PRR= 1.89, CI= 1.47-2.42) and a significantly decreased risk with cefdinir 
(PRR= 0.16, CI= 0.08-0.29) and cefotaxime (PRR= 0.32, CI= 0.12-0.85) as compared to 
controls experiencing non-anaphylaxis adverse events. Both ROR and PRR were non-
significant for cefditoren, cefpodoxime, ceftazidime and ceftibuten. cOnclusiOns: 
Among 3rd generation cephalosporins, which are commonly used to treat bacte-
rial infections, patients having anaphylaxis ADRs were found to have significantly 
higher odds of cefoperazone and ceftriaxone exposure, but significantly lower odds 
of cefdinir and cefotaxime exposure compared to patients having other ADRs.
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Objectives: The objective of this study was to describe the antibiotic treatment 
patterns among patients with newly-diagnosed Lyme disease (LD). Some published 
treatment guidelines specify short-course antibiotic treatment for early LD lasting 
10-28 days, but there are conflicting recommendations. Little is known about real-
world LD treatment patterns. MethOds: Patients newly diagnosed with LD (ICD-9: 
088.81) in 2010-2012 were identified in the Truven Health MarketScan® Commercial 
and Medicare Supplemental Databases. Continuous enrollment was required one 
year pre- and three months post-LD diagnosis. Patients were excluded if they used 
antibiotics in the prior 90 days or had another infection diagnosis in the week 
prior to or following the index LD diagnosis. Outcomes were the portion of patients 
receiving antibiotics within 14 days post-LD diagnosis, as well as duration and 
types of antibiotics received. Results: A total of 10,783 patients met the selec-
tion criteria (mean age 42.0 years [SD= 20.6]; 44% female). Of these patients, 64% 
initiated antibiotic therapy within 14 days of their index LD diagnosis. On average, 
patients used antibiotics for 28.3 (SD= 27.4, median= 21.0) days following a new LD 
diagnosis. The majority of patients (78.3%) were treated with antibiotics for 10-30 
days; relatively few patients (3%) were treated for less than 10 days. A substan-
tial portion (18.7%) were treated with antibiotics for more than one month, with 
some treated for more than two (5.3%) or three months (2.9%). Newly-diagnosed LD 
patients were treated primarily with types of antibiotics mentioned in published 
treatment guidelines (doxycycline [73%], amoxicillin [22%], cefuroxime [4%]), with 
very little use of antibiotics deviating from guidelines (e.g., azithromycin [3%] and 
ciprofloxacin [1%]). cOnclusiOns: Optimal treatment for newly-diagnosed LD 
remains undefined. Results of this study substantiate anecdotal evidence that a 
substantial portion of LD patients are being treated with antibiotics for longer than 
advocated in published guidelines or not at all.
